FRANKFURT (Reuters) - A spokesman for GlaxoSmithKline GSK.L on Wednesday declined to comment on a report by IFR, saying the British drugmaker was selling a block of shares in Hindustan Unilever HLL.NS worth $3.4 billion on the open market.
In December 2018 GSK agreed to sell malted drink brand Horlicks and other nutrition brands to Unilever ULVR.L for $3.8 billion. At the time it accepted as partial payment a stake in a planned joint venture between GSK's Indian business - whose main product is Horlicks - and Unilever's Indian unit Hindustan Unilever.
Reporting by Ludwig Burger, editing by Louise Heavens
Our Standards: The Thomson Reuters Trust Principles.